ABBV

SEC source: 0001415889-24-004428 · form4-02202024_100233.xml · derivative · entry 5

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,998

Underlying: Common Stock · 28,998 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,666 on February 15, 2025, 9,666 on February 15, 2026, and 9,666 on February 15, 2027.

SEC source: 0001415889-24-004428 · form4-02202024_100233.xml · nonDerivative · entry 4

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,664

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004428 · form4-02202024_100233.xml · nonDerivative · entry 3

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,872

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004428 · form4-02202024_100233.xml · nonDerivative · entry 2

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 54,492

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-004428 · form4-02202024_100233.xml · nonDerivative · entry 1

RICHMOND TIMOTHY J. · CIK 0001563523 · EVP, CHIEF HR OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,934

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-25-003337 · form4a-02072025_040201.xml · derivative · entry 5

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,868

Underlying: Common Stock · 13,868 shares

Expires 2034-02-14

F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 7,775 on February 15, 2025, 7,775 on February 15, 2026, and 7,774 on February 15, 2027.

F6 · derivative.exercise_price: Due to an administrative error the exercise price for options awarded February 15, 2024 was previously reported as $0 but the correct value of $175.28 is reflected in this amendment.

SEC source: 0001415889-25-003337 · form4a-02072025_040201.xml · nonDerivative · entry 4

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,313

F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-25-003337 · form4a-02072025_040201.xml · nonDerivative · entry 3

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,173

F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-25-003337 · form4a-02072025_040201.xml · nonDerivative · entry 2

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,697

F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-25-003337 · form4a-02072025_040201.xml · nonDerivative · entry 1

Thakkar Roopal · CIK 0002004979 · EVP, R&D and CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,125

F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024.

SEC source: 0001415889-24-002828 · form4-02062024_050202.xml · derivative · entry 3

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,837

Underlying: Common Stock · 2,919 shares

Expires 2032-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-24-002828 · form4-02062024_050202.xml · nonDerivative · entry 2

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,377

F1 · shares: This sale was executed pursuant to a Rule 10b5-1 plan that was entered into by the Reporting Person on February 14, 2023.

SEC source: 0001415889-24-002828 · form4-02062024_050202.xml · nonDerivative · entry 1

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,296

SEC source: 0001415889-24-000327 · form4-01032024_050102.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,266

Underlying: Common Stock · 250 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-000335 · form4-01032024_100107.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,285

Underlying: Common Stock · 48 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-24-000345 · form4-01032024_100158.xml · derivative · entry 1

Quaggin Susan E · CIK 0001997505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64

Underlying: Common Stock · 64 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

SEC source: 0001415889-23-016990 · form4-12282023_051202.xml · nonDerivative · entry 1

Donoghoe Nicholas · CIK 0001762951 · EVP, CHIEF BUS/STRAT OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,903

F1 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.72 to $154.73, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-23-013895 · form4-10032023_051001.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,139

Underlying: Common Stock · 50 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-013896 · form4-10032023_051004.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,750

Underlying: Common Stock · 259 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-013605 · form4-09272023_050901.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 523,294

SEC source: 0001415889-23-013148 · form4-09112023_050901.xml · nonDerivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,121

SEC source: 0001415889-23-011768 · form4-08022023_090805.xml · nonDerivative · entry 2

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 565,294

F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.85 to $150.69 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-23-011768 · form4-08022023_090805.xml · nonDerivative · entry 1

GONZALEZ RICHARD A · CIK 0001239127 · Director · CHAIRMAN OF THE BOARD AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 625,294

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.85 to $149.59 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-23-010773 · form4-07052023_050701.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,001

Underlying: Common Stock · 55 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-010774 · form4-07052023_050703.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,254

Underlying: Common Stock · 287 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-007908 · form4-05122023_050501.xml · nonDerivative · entry 1

Strom Carrie C · CIK 0001811896 · SVP & PRES GLOBAL ALLERG AESTH

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,024

SEC source: 0001415889-23-007664 · form4-05092023_050502.xml · nonDerivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,992

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007665 · form4-05092023_050504.xml · nonDerivative · entry 1

BURNSIDE WILLIAM H.L. · CIK 0001563579 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,433

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007666 · form4-05092023_050507.xml · nonDerivative · entry 1

FREYMAN THOMAS C · CIK 0001239126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,226

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007669 · form4-05092023_090558.xml · nonDerivative · entry 1

AUSTIN ROXANNE S · CIK 0001061632 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,933

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007671 · form4-05092023_090521.xml · nonDerivative · entry 1

Hart Brett J · CIK 0001466338 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,947

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007673 · form4-05092023_090514.xml · nonDerivative · entry 1

MEYER MELODY B · CIK 0001706126 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,973

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007674 · form4-05092023_090547.xml · nonDerivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,034

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007675 · form4-05092023_090541.xml · nonDerivative · entry 1

Roberts Rebecca B · CIK 0001355580 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,203

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007677 · form4-05092023_050501.xml · nonDerivative · entry 1

TILTON GLENN F · CIK 0001194624 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,039

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007678 · form4-05092023_050504.xml · nonDerivative · entry 1

WADDELL FREDERICK H · CIK 0001223690 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,433

F1 · shares: These are restricted stock units awarded under the AbbVie Amended and Restated 2013 Incentive Stock Program (the "Program"). They will be paid, on a one-to-one basis, in shares of AbbVie common stock on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined in the Program).

SEC source: 0001415889-23-007107 · form4-05022023_090519.xml · derivative · entry 1

TILTON GLENN F · CIK 0001194624 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,700

Underlying: Common Stock · 2,230 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The cash equivalent of 2,230 AbbVie stock equivalent units in the Abbott account was paid to the director upon his retirement from Abbott's board on April 28, 2023.

F2 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

F2 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

F2 · balance_after: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-006965 · form4-04272023_050402.xml · derivative · entry 3

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 12,258

Underlying: Common Stock · 6,130 shares

Expires 2032-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-006965 · form4-04272023_050402.xml · nonDerivative · entry 2

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,330

F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.00 to $165.03, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-23-006965 · form4-04272023_050402.xml · nonDerivative · entry 1

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 41,460

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-006720 · form4-04192023_050401.xml · nonDerivative · entry 2

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,330

F2 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.00 to $162.14, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-23-006720 · form4-04192023_050401.xml · nonDerivative · entry 1

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 35,830

F1 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.00 to $161.95, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-23-006300 · form4-04052023_050401.xml · derivative · entry 3

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,520

Underlying: Common Stock · 3,520 shares

Expires 2031-02-17

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-006300 · form4-04052023_050401.xml · nonDerivative · entry 2

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,377

SEC source: 0001415889-23-006300 · form4-04052023_050401.xml · nonDerivative · entry 1

Siatis Perry C · CIK 0001951400 · EVP, GC AND SECRETARY

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,897

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-006301 · form4-04052023_050407.xml · derivative · entry 3

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,002 shares

Expires 2030-02-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

SEC source: 0001415889-23-006301 · form4-04052023_050407.xml · nonDerivative · entry 2

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,829

F1 · shares: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.05, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001415889-23-006301 · form4-04052023_050407.xml · nonDerivative · entry 1

Sorg Elaine K. · CIK 0001832571 · SVP, US COMMERCIAL OPERATIONS

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,831

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001415889-23-006073 · form4-04042023_050401.xml · derivative · entry 1

RAPP EDWARD J · CIK 0001171780 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,727

Underlying: Common Stock · 243 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

SEC source: 0001415889-23-006074 · form4-04042023_050406.xml · derivative · entry 1

Alpern Robert J · CIK 0001448074 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,856

Underlying: Common Stock · 47 shares

Expires not disclosed

F1 · derivative.exercise_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F1 · derivative.expiration_date: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.